Skip to main content
. 2018 Aug 6;2018:6736721. doi: 10.1155/2018/6736721

Figure 4.

Figure 4

Expression of hippocampal UCP2 and p-AKT in the presence or absence of antisense oligonucleotide (ASO) treatment in SE rats. (a) Treatment with ASO diminished UCP2 mRNA expression in rats 5 days after SE onset. ∗p < 0.001 versus control and 5 d ep ASO; &p < 0.001 versus 5 d ep; (b) UCP2 protein expression presented high levels 5 days after SE. ASO treatment successfully decreased UCP2 protein expression 5 days after SE. ∗p < 0.001 versus control; #p < 0.001 versus control and SE 5 d; (c) p-AKT expression diminished after ASO treatment. ∗p < 0.001 versus control; #p < 0.001 versus control and SE 5 d according to two-way ANOVA followed by Tukey's post hoc tests. Values are means ± SEM.